To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
GSK spinout SR One collects $500m for fund
SR One, a biotech venture firm that recently spun out from GlaxoSmithKline, has raised $500 million for its new fund.
